Neural cell adhesion molecule 2 as a target molecule for prostate and breast cancer gene therapy

Cancer Science

Volumn 102, Issue 4, 2011, Pages 808-814

  Takahashi, Shu ^a,b   Kato, Kazunori ^a,c   Nakamura, Kiminori ^a   Nakano, Rika ^b   Kubota, Kazuishi ^b   Hamada, Hirofumi ^a  

^a SAPPORO MEDICAL UNIVERSITY   (Japan)

^b DAIICHI SANKYO CO   (Japan)

^c JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; FLUOROURACIL; FZ33 PROTEIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY LNI 29; NEURAL CELL ADHESION MOLECULE 2; PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; URACIL PHOSPHORIBOSYLTRANSFERASE;

ANIMAL CELL; ARTICLE; BREAST CANCER; CANCER GENE THERAPY; CELL STRAIN LNCAP; HUMAN; HUMAN CELL; HYBRIDOMA; LIVER CELL CARCINOMA; MALE; MOUSE; MYELOMA; NONHUMAN; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; AMINO ACID SEQUENCE; ANIMALS; ANIMALS, NEWBORN; ANTIBODIES, MONOCLONAL; ANTIMETABOLITES, ANTINEOPLASTIC; BLOTTING, WESTERN; BREAST NEOPLASMS; CELLS, CULTURED; DRUG RESISTANCE, NEOPLASM; FEMALE; FLOW CYTOMETRY; FLUOROURACIL; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; HYBRIDOMAS; IMMUNIZATION; IMMUNOGLOBULIN G; IMMUNOPRECIPITATION; MALE; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; NEURAL CELL ADHESION MOLECULE L1; PENTOSYLTRANSFERASES; PROSTATE; PROSTATIC NEOPLASMS; RNA, SMALL INTERFERING; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR CELLS, CULTURED;

EID: 79952761656     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2011.01855.x     Document Type: Article

References (30)

1. Akaza H. Trends in primary androgen depletion therapy for patients with localized and locally advanced prostate cancer: Japanese perspective. Cancer Sci 2006; 97: 243-7.
2. Kasper S, Cookson MS. Mechanism leading to the development of hormone-resistant prostate cancer. Urol Clin N Am 2006; 33: 201-10.
3. Macrae EJ, Giannoudis A, Ryan R et al. Gene therapy for prostate cancer: current strategies and new cell-based approaches. Prostate 2006; 66: 470-94.
4. Slovin SF. Emerging role of immunotherapy in the management of prostate cancer. Oncology 2007; 21: 326-33.
5. McNeel DG. Prostate cancer immunotherapy. Curr Opin Urol 2007; 17: 175-81.
6. LinksHinata N, Shirakawa T, Terao S et al. Progress report on phase I/II clinical trial of Ad-OC-TK plus VAL therapy for metastatic or locally recurrent prostate cancer: initial experience at Kobe University. Int J Urol 2006; 13: 834-7.
7. Freytag SO, Stricker H, Pegg J et al. Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer. Cancer Res 2003; 63: 7497-506.
8. Schepelmann S, Hallenbeck P, Ogilvie LM et al. Systemic gene-directed enzyme prodrug therapy of hepatocellular carcinoma using a targeted adenovirus armed with carboxypeptidase G2. Cancer Res 2005; 65: 5003-8.
9. Kanai F, Kawakami T, Hamada H et al. Adenovirus-mediated transduction of Escherichia coli uracil phosphoribosyltransferase gene sensitizes cancer cells to low concentrations of 5-fluorouracil. Cancer Res 1998; 58: 1946-51.
10. Seo E, Abei M, Wakayama M et al. Effective gene therapy of biliary tract cancers by a conditionally replicative adenovirus expressing uracil phosphoribosyltransferase: significance of timing of 5-fluorouracil administration. Cancer Res 2005; 65: 546-52.
11. Magnusson MK, Henning P, Myhre S et al. Adenovirus 5 vector genetically re-targeted by an Affibody molecule with specificity for tumor antigen HER2/neu. Cancer Gene Ther 2007; 14: 468-79.
12. Wartlick H, Michaelis K, Balthasar S, Strebhardt K, Kreuter J, Langer K. Highly specific HER2-mediated cellular uptake of antibody-modified nanoparticles in tumour cells. J Drug Target 2004; 12: 461-71.
13. Jiang M, Shi W, Zhang Q et al. Gene therapy using adenovirus-mediated full-length anti-HER-2 antibody for HER-2 overexpression cancers. Clin Cancer Res 2006; 12: 6179-85.
14. Volpers C, Thirion C, Biermann V et al. Antibody-mediated targeting of an adenovirus vector modified to contain a synthetic immunoglobulin g-binding domain in the capsid. J Virol 2003; 77: 2093-104.
15. Tanaka T, Huang J, Hirai S et al. Carcinoembryonic antigen-targeted selective gene therapy for gastric cancer through FZ33 fiber-modified adenovirus vectors. Clin Cancer Res 2006; 12: 3803-13.
16. Suzuki K, Nakamura K, Kato K, Hamada H, Tsukamoto T. Exploration of target molecules for prostate cancer gene therapy. Prostate 2007; 67: 1163-73.
17. Hanai N, Shitara K, Yoshida H. Generation of monoclonal antibodies against human lung squamous cell carcinoma and adenocarcinoma using mice rendered tolerant to normal human lung. Cancer Res 1986; 46: 4438-43.
18. Paoloni-Giacobino A, Chen H, Antonarakis SE. Cloning of a novel human neural cell adhesion molecule gene (NCAM2) that maps to chromosome region 21q21 and is potentially involved in Down syndrome. Genomics 1997; 43: 43-51.
19. Crnic I, Strittmatter K, Cavallaro U et al. Loss of neural cell adhesion molecule induces tumor metastasis by up-regulating lymphangiogenesis. Cancer Res 2004; 64: 8630-8.
20. Jensen M, Berthold F. Targeting the neural cell adhesion molecule in cancer. Cancer Lett 2007; 258: 9-21.
21. Alenius M, Bohm S. Identification of a novel neural cell adhesion molecule-related gene with a potential role in selective axonal projection. J Biol Chem 1997; 272: 26083-6.
22. Alenius M, Bohm S. Differential function of RNCAM isoforms in precise target selection of olfactory sensory neurons. Development 2003; 130: 917-27.
23. Edwards S, Campbell C, Flohr P et al. Expression analysis onto microarrays of randomly selected cDNA clones highlights HOXB13 as a marker of human prostate cancer. Br J Cancer 2005; 92: 376-81.
24. Nelson EA, Walker SR, Li W, Liu XS, Frank DA. Identification of human STAT5-dependent gene regulatory elements based on interspecies homology. J Biol Chem 2006; 281: 26216-24.
25. Nevalainen MT, Ahonen TJ, Yamashita H et al. Epithelial defect in prostates of Stat5a-null mice. Lab Invest 2000; 80: 993-1006.
26. Hobisch A, Eder IE, Putz T et al. Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res 1998; 58: 4640-5.
27. Lee SO, Chun JY, Nadiminty N, Lou W, Gao AC. Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression. Prostates 2007; 67: 764-73.
28. Mori R, Xiong S, Wang Q et al. Gene profiling and pathway analysis of neuroendocrine transdifferentiated prostate cancer cells. Prostate 2009; 69: 12-23.
29. Mizuguchi H, Koizumi N, Hosono T et al. CAR- or alpha v integrin-binding ablated adenovirus vectors, but not fiber-modified vectors containing RGD peptide, do not change the systemic gene transfer properties in mice. Gene Ther 2004; 9: 769-76.
30. Ishii K, Nakamura K, Kawaguchi S et al. Selective gene transfer into neurons via Na, K-ATPase b1. Targeting gene transfer with monoclonal antibody and adenovirus vector. J Gene Med 2008; 10: 597-609.